Transcriptome and SARS-CoV-2 Biological Network Directed Analysis for Better Therapeutic Development

Background: It has been almost 3.5 years since the first SARS-CoV-2 virus was first reported in the city of Wuhan. While the FDA has approved a number of drugs for Covid-19, the presence of the disease and its symptoms underscores the continued demand for an improved treatment option to effectively address the existing challenges. In this study, our goal is to identify pivotal protein targets, strongly correlated across lung, blood, and peripheral blood mononuclear cell (PBMC) transcriptomics datasets, to suggest promising targets for comprehensive therapeutic development across multiple tissues.